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Abstract Twenty patients with urinary tuberculosis were
treated with oﬂoxacin (200 mg/day, 6 months), rifampin
(600 mg/day, 3 months) and isoniazid (300 mg/day,
3 months) between 1989 and 1990. All patients were
new cases, diagnosed by observation and/or isolation of
Mycobacterium tuberculosis in one of the three morning
urine samples. Bacteriological culture conversion (nega-
tivization) was assessed as a clinical guide of eﬃcacy,
comparing it, as the only parameter, against a control
group (150 patients) with urinary tuberculosis who
received conventional therapy. Bacteriological follow-up
studies were performed in both groups monthly for
6 months, then again 6 months later and then every year
for 10 years after completion of treatment. In the 20
patients, the initial culture was positive with over 100
colonies per culture (>50%); the smear was positive in
45% of the patients (most were 2+). All strains were
susceptible to rifampin, isoniazid and oﬂoxacin. Two
patients discontinued treatment. Beginning with the ﬁrst
month of treatment, the bacteriological conversion was
100%, 89.5% and 100% in the remaining controls. In the
control group, which received conventional treatment,
the conversion was: 90%, 87%, 93% and 100% in the
remaining controls. Treatment with oﬂoxacin resulted in
a bacteriological conversion similar to that following
conventional treatment (p>0.05, Fisher’s exact test).
After 10 years of patient follow-up, we conclude that
oﬂoxacin, in combination with rifampin and isoniazid
(both for 3 months only is eﬀective against M. tubercu-
losis, providing satisfactory bacteriological and clinical
eﬃcacy.
Keywords Tuberculosis treatment Æ Urinary
tuberculosis Æ Oﬂoxacin Æ Tuberculosis conversion
Introduction
The incidence of tuberculosis, in all its forms of clinical
presentation, remains high [11]. Although treatment
guidelines are well deﬁned, this is a ﬁeld of continuous
research, the objectives of which are: (1) to reduce
treatment duration without losing eﬃcacy, (2) to de-
crease the side eﬀects of the drugs used, and (3) to en-
courage adequate patient cooperation [22]. Currently,
treatment duration is either 6 months (short treatment)
or 9 months for both pulmonary and extrapulmonary
sites [3, 14, 16, 21]. Both treatments combine isoniazid
and rifampin, adding pyrazinamide in the short regimen.
However, although the eﬃcacy of these drugs has been
shown, signiﬁcant side eﬀects occur, and thus new
therapeutic possibilities must be investigated [13].
The ﬂuoroquinolones, with activity againstMycobac-
terium tuberculosis, are of interest in the ﬁeld of
tuberculosis treatment as they combine a favorable
pharmacokinetics and low toxicity [6, 9, 20, 23]. Oﬂox-
acin, a ﬂuoroquinolone which acts on DNA gyrase, has
high bioavailability and reaches high blood concentra-
tions, with renal excretion greater than 90% during the
ﬁrst 24 h after its administration. Furthermore, previous
studies have demonstrated the eﬃcacy of oﬂoxacin as a
monotherapy [24] and in combination with other antit-
uberculosis drugs in the treatment of primary tubercu-
losis. Thus, in 1989, we began to investigate the eﬃcacy
of oﬂoxacin in combination with other antituberculosis
drugs in the treatment of urinary tuberculosis (UTB) [1].
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The other antituberculosis drugs chosen were isoniazid
and rifampin, which show signiﬁcant activity in steril-
izing tuberculous lesions [8] and do not cause antago-
nism or cross-resistance with oﬂoxacin [10].
The bacteriological conversion rate of the urinary
samples studied as well as the follow-up performed over
the last 10 years for the 20 patients included within the
study were considered as markers of the eﬃcacy of the
treatment as assessed by the detection of relapse or
treatment failure. This study was compared with a
control group of 150 patients treated with the short
6-month treatment regimen.
Materials and methods
Patients: inclusion criteria
Patients treated with oﬂoxacin:
Twenty patients with conﬁrmed UTB were admitted into this
study between April 1989 and March 1990. Pregnant women,
nursing mothers and children under 15 years of age were ex-
cluded (Table 1). UTB was diagnosed by observation and/or
isolation of M. tuberculosis in one of three morning urine
samples sent to the laboratory.
Control group:
The controls consisted of 150 patients with UTB. All of the
patients were new cases and had not been previously diag-
nosed with or treated for tuberculosis. Informed consent,
according to the established guidelines, was obtained from all
patients.
Deﬁnitions
New case:
Patient in whom there was no knowledge of tuberculosis or
previous antituberculosis treatment.
Treatment failure:
No bacteriological conversion was produced after 3 months of
treatment.
Relapse:
Finding of a positive smear and/or culture of M. tuberculosis in
patients who completed the 6 months of treatment.
Probable cure:
Patient who, once the 6 months of treatment was completed,
did not suﬀer any relapse or treatment failure.
Cure:
Patient in whom no relapse was observed once the treatment
had been completed and after 12 months of further observa-
tion.
Microbiological investigation and follow-up
M. tuberculosis was identiﬁed by sample decontamination using 6%
sulfuric acid [15], examination by ﬂuorescence microscopy, and
culture in Lo¨wenstein-Jensen and pyruvate medium, incubating the
cultures at 35 C for up to 8 weeks. Once growth was observed in
solid media, M. tuberculosis complex probes (Accuprobe, Gen-
Probe, now bioMe´rieux) were used for identiﬁcation.
Antibiotic treatment and follow-up
Oﬂoxacin group Oﬂoxacin was administered orally (200 mg/day)
for 6 months. During the ﬁrst 3 months, oral rifampin (600 mg/
day) and oral isoniazid (300 mg/day) were added.
Control group Oral rifampin (600 mg/day) and oral isoniazid
(300 mg/day) were administered during the 6-month treatment
period. During the ﬁrst 2 months, pyrazinamide (25 mg/kg/day,
orally) and ethambutol (25 mg/kg/day, orally) were added.
Microbiological follow-up
During the treatment period, microbiological follow-up consisted
of a monthly study of three morning urine samples. This was re-
peated after 6 month and every year after the completion of the
treatment for 10 years.
Clinical controls
The baseline studies included a complete blood proﬁle, renal and
hepatic function tests, a chest X-ray, and an endovenous urogra-
phy. The blood tests, as well as the renal and hepatic function
tests, were repeated every month. The intravenous urography was
repeated after 3 and 6 months of treatment.
Determination of M. tuberculosis susceptibility
To oﬂoxacin
Oﬂoxacin (DL 8280 Hoechst-Roussel, now Aventis) susceptibility
was tested in Mycobacteria 7H11 agar medium (Difco, Detroit,
Mich,, USA) with Middlebrook OADC enrichment (Difco). First,
a mother solution was prepared with 10 mg of oﬂoxacin dissolved
in 0.3 ml of 0.1 N NaOH; 9.4 ml of H2O were then added and
ﬁnally 0.3 ml of 0.1 N HCl, resulting in a 1,000 lg/ml solution,
pH 5.8. This solution was diluted appropriately with water and
added aseptically to previously sterilized medium to obtain the ﬁnal
concentrations of 1 and 4 lg/ml. The medium, with the antibiotics,
was added to screw-cap tubes and solidiﬁed in a tilted position.
Inoculi were prepared by diluting each strain to a turbidity equal to
Table 1. Patients included in the protocol. F Female, M male
Patient Age Sex Symptoms
1 50 M Cystitis
2 29 F Nephritic colic
3 60 M Epididymitis
4 50 F Lumbar pain
5 64 M Prostatitis
6 45 M Lumbar pain
7 16 F Cystitis
8 64 F Cystitis
9 64 F Cystitis, general disorders
10 67 M Cystitis
11 58 M Cystitis
12 63 F Lumbar pain
13 62 M Lumbar pain
14 48 M Bilateral epididymitis
15 46 F Cystitis, lumbar pain
16 56 F Lumbar pain
17 60 M Epididymitis, prostatitis
18 54 F Pyelonephritis, incontinence
19 56 M Lumbar pain
20 35 F Lumbar pain
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a McFarland no. 1 standard, followed by a dilution to 1:100 [9].
Once the inoculum was added, strains were considered susceptible
if they were inhibited by 1 lg oﬂoxacin/ml. Strains able to grow in
the presence of either 1 lg oﬂoxacin/ml or 4 lg oﬂoxacin/ml were
considered resistant.
To rifampin and isoniazid
Susceptibility rifampin and isoniazid was tested using the Canetti’s
proportions method [4]. A strain was considered resistant when the
proportion of growth on drug-containing medium was equal or
more to 1% of the growth observed on drug-free medium.
Statistical study
The diﬀerences in the results between the therapeutic regimens were
compared using the EPI INFO, version 6.0, statistical package
(USD Incorporated, Stone Mountain, Ga., USA). Proportions
were compared by v2 test or Fisher’s exact test when appropriate;
means were calculated using Student’s t test. Negativization of the
culture served as endpoint. The diﬀerence between the therapeutic
regimens was considered to be statistically signiﬁcant for values of
p=<0.05.
Results
Patient population
Two patients withdrew from the protocol, one of them
due to pregnancy 4 months after initiation of treatment.
Her clinical, analytical and microbiological evolution
during this period had been satisfactory and both her
pregnancy and childbirth developed normally. The other
patient suﬀered from acute hepatopathy at the onset of
the protocol and a decision was made to exclude him.
One patient with left epididymitis presented discomfort
that could be attributed to the testis; the pain gradually
subsided after completion of the protocol and he did
not require an epididymectomy. The evolution of the
Table 2. Eﬀect on the smear and on Mycobacterium tuberculosis culture of the administration of oﬂoxacin, rifampin, and isoniazid to 20
patients. –, 1+, 2+Microscopic observation according to CDC guidelines, x conﬂuent growth, Arabic numbers number of colonies in the
culture
Patient Initial
bacteriology
Follow-up
1 month 2 months 3 months 4 months 5 months 6 months 12 months 10 years
1 Smear: 2+ 2+ – – – – – – –
Culture: x – – – – – – – –
2 Smear: + – – – – Withdrawal
Culture: 10 – – – –
3 Smear: – – – – – – – – –
Culture: 20 – – – – – – – –
4 Smear: 2+ – – – – – – – –
Culture: x – – – – – – – –
5 Smear: – – – – – – – – –
Culture: x – – – – – – – –
6 Smear: 2+ 1+ 1 – – – – – –
Culture: x – 1 – – – – – –
7 Smear: 2+ – – – – – – – –
Culture: x – – – – – – – –
8 Smear: – Withdrawal
Culture: 8
9 Smear: – – – – – – – – –
Culture: 4 – – – – – – – –
10 Smear: 3+ – – – – – – – –
Culture: x – – – – – – – –
11 Smear: 2+ – – – – – – – –
Culture: x – – – – – – – –
12 Smear: 1+ – – – – – – – –
Culture: 20 – – – – – – – –
13 Smear: – – 30 – – – – – –
Culture: 30 – 30 – – – – – –
14 Smear: 1+ – – – – – – – –
Culture: 100 – – – – – – – –
15 Smear: – – – – – – – – –
Culture: 6 – – – – – – – –
16 Smear: – – – – – – – – –
Culture: 10 – – – – – – – –
17 Smear: – – – – – – – – –
Culture: 100 – – – – – – – –
18 Smear: – – – – – – – – –
Culture: 1 – – – – – – – –
19 Smear: – – – – – – – – –
Culture: x – – – – – – – –
20 Smear: – – – – – – – – –
Culture: 100 – – – – – – – –
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remaining patients was satisfactory, the symptoms sub-
siding once the treatment began. Patient collaboration
was very good, and no patient complained that he or she
could not tolerate treatment.
Microbiological studies and follow-up
A microbiological diagnosis was required by the proto-
col. Cultures were positive in the 20 patients; in more
than half, the number of colonies was greater than 100.
The staining was positive in nine patients (45%), and
most were 2+ (Table 2). All of the strains of M. tuber-
culosis isolated were susceptible to the antituberculosis
antibiotics studied. Positive cultures were observed
in the second month only in patients 6 and 13, with
one and 30 colonies respectively. Acid-fast bacilli
were observed in the ﬁrst month of treatment in two
patients (1 and 6); the subsequent examinations were
negative.
Clinical controls
No changes were observed in the hemogram or in renal
function during follow-up. The transaminase levels of
four patients increased during the ﬁrst 3 months of
treatment but liver function returned to normal when
rifampin and isoniacid were withdrawn. Seven patients
had an elevated ESR before treatment which returned to
the normal range in ﬁve patients after 4 months of
treatment. Of the patients whose ESR remained persis-
tently high, one had rheumatoid arthritis and the other,
with no previous history, still undergoes control evalu-
ation. Up to now, this patient has not presented with
disease recurrence.
Seventeen patients had radiological evidence of
changes in the renal parenchyma which remained un-
changed at the end of treatment in ten patients and
improved in two patients. The function of ﬁve kidneys
deteriorated during treatment. These were all previously
damaged kidneys. A percutaneous nephrostomy was left
indwelling for 2 months in two patients but failed to
improve renal function. Nephrectomy was not per-
formed and the patients with nonfunctioning kidneys
still undergo control evaluation regularly. Patient num-
ber 13 was allergic to iodine and was therefore evaluated
by ultrasound.
Changes in the calices or ureters were observed in
12 patients. Four improved radiologically and eight
remained unchanged during treatment. None of these
patients were considered for conservative surgical
treatment. One patient presented bladder involvement
which markedly improved within the ﬁrst few months
of treatment. Two patients who presented with
prostatic involvement were monitored by a pelvic CT
scan and both improved, showing a normal mor-
phology of the prostate at the end of treatment. The
radiological evolution of the patients is described in
Table 3.
Table 3. Evolution of urographic ﬁndings
Patient Pre-treatment 3 months 6 months
1 Chronic pyelonephritis of left kidney; left renal
function poor; large bladder ﬁlling defect
Nonfunctioning left kidney with
calciﬁcations; bladder normal
Similar to previous ﬁndings
2 Small papillary lesion in right kidney Normal Normal
3 Normal Normal Normal
4 Cavitations in left renal parenchyma; diverticulum
in left upper calyx; stenosis in left distal ureter
Nonfunctioning left kidney Similar to ﬁndings at ﬁrst
evaluation
5 Normal Normal Normal
6 Right renal function poor; stenosis in upper calyx
of right kidney
Nonfunctioning right kidney Similar to previous ﬁndings
7 Right kidney with chronic pyelonephritis;
right renal function poor
Nonfunctioning right kidney Similar to previous ﬁndings
8 NR
9 Dilated upper calyx of left kidney Similar to previous ﬁndings Similar to previous ﬁndings
10 Dilated left renal cavities; left renal function poor Size of left kidney smaller;
left renal function poor
Similar to previous ﬁndings
11 Chronic pyelonephritis of left kidney; left renal
function poor
Nonfunctioning left kidney Similar to previous ﬁndings
12 Necrosis of upper pole of left kidney Similar to previous ﬁndings Similar to previous ﬁndings
13 NR
14 Stenosis in left distal ureter; enlarged prostate
with cavitations inside
Ureteral stenosis disappeared Normal
15 Scars in right renal parenchyma Similar to previous ﬁndings Similar to previous ﬁndings
16 Chronic pyelonephritis of left kidney;
left renal function poor
Nonfunctioning left kidney Similar to previous ﬁndings
17 Small renal scars Similar to previous ﬁndings Similar to previous ﬁndings
18 Normal Normal Normal
19 Left urinary tract slightly dilated Normal Normal
20 Right urinary tract slightly dilated;
right renal cavities
Normal Normal
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Bacteriological conversion and comparison
between two groups
Once the treatment was initiated, the bacteriological
conversion of the cultures (negativization) in the oﬂox-
acin group was 100% in the ﬁrst month, 89.5% in the
second and 100% in the remaining months. In the 150
patients of the control group, who also had urinary tu-
berculosis, the following bacteriological conversion rates
of the cultures were observed month by month: 90%,
87%, 93%, and 100% in the remaining months. The
overall evolution of the cultures in both series is de-
scribed in Table 4. No statistically signiﬁcant diﬀerences
were found between the two groups.
Discussion
All of the strains of M. tuberculosis were susceptible to
isoniazid and rifampin. In addition, the MICs observed
in response to oﬂoxacin were less than 1 lg/ml, similar
to those reported by other authors [17, 18, 26]. The
dosage of 200 mg oﬂoxacin every 12 h, together with the
favorable pharmacokinetics, make it possible to reach
mean concentrations in urine that widely exceeds the
MICs. The absence of cross- resistance and the possi-
bility of a synergistic eﬀect of oﬂoxacin with the antit-
uberculosis agents used suggest promising results with
this drug. Nonetheless, we believe that the use of isoni-
azid and rifampin in the ﬁrst 3 months of treatment was
fundamental to successful treatment of UTB, due to
their rapid sterilization of the lesions, eliminating both
the extracellular population as well as that present in the
closed lesions and in the macrophages [8]. The treatment
regimen described in this study, which was aimed at
alleviating some of the inconveniences observed with the
established regimens without diminishing therapeutic
eﬃcacy, is based on the properties of the quinolone
oﬂoxacin [2, 5, 7].
The clinical results measured in the follow-up studies
were good; all patients recovered, and no relapses were
observed. Only one patient had to withdraw from the
study due to signiﬁcant liver toxicity, which, based on
the patient’s symptoms, we believe may have been due to
rifampicin and isoniazid. Others patients had increased
transaminase levels which returned to normal when
these drugs were discontinued. Therefore, there are no
objective reasons to attribute hepatic, renal, or hema-
tological toxicity or teratogenic eﬀects to oﬂoxacin in
patients who were withdrawn from the protocol.
Although the negativization of the sputum of pa-
tients with pulmonary tuberculosis is generally achieved
within 2 months when the therapeutic regimen incor-
porates isoniazid and rifampicin, no speciﬁc data are
available for genitourinary tuberculosis. Our results
with a treatment regimen that includes oﬂoxacin indi-
cate that 100% negativization is reached after the third
month of therapy; in the second month of treatment,
there were positive cultures from two patients, with 1
and 30 colonies.
The strict follow-up of the patients during the last
10 years, during which time no abnormalities occurred,
shows the adequacy of the therapeutic regimen described
here. Thus, it is not surprising that no signiﬁcant dif-
ferences are observed when these patients were com-
pared to those in the control group.
However, while the potential role of the ﬂuoroqui-
nolones has been studied [19], larger studies are needed
aimed at evaluating new therapeutic alternatives which,
with equal eﬃcacy, can improve treatment while
avoiding the adverse side eﬀects and strengthening the
degree of patient cooperation. In addition, it should be
noted that a single-drug treatment was used in the
middle of our therapeutic regimen. If the sterilizing
power of the two antituberculosis drugs– rifampicin and
isoniazid– is fundamental at the onset of the treatment,
the activity of oﬂoxacin can later culminate therapy,
assuming, as stated by Yew [26], that ‘‘it is not a su-
perﬂuous association.’’ We believe that this approach
opens up a new therapeutic perspective, which, although
novel with respect to the current literature, nonetheless
bases its eﬃcacy on a careful follow-up over 10 years.
Finally, in agreement with Jacobs [12], we feel that the
ﬂuorquinolones present a ‘‘considerable potential if they
are used sensibly’’ and, although controversies remain
[25], the bacteriological conversion of the cultures of
M. tuberculosis is proof of their therapeutic eﬃcacy.
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